Rg1 can improve insulin resistance and has shown good therapeutic potential in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) combined with fatty liver, diabetic cerebral infarction, and diabetic cardiomyopathy complications [16,17]. Here, PPP1R3A is linked to fatty liver disease.